brand-name drug

Also found in: Thesaurus, Medical.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.brand-name drug - a drug that has a trade name and is protected by a patent (can be produced and sold only by the company holding the patent)
drug - a substance that is used as a medicine or narcotic
generic drug - when the patent protection for a brand-name drug expires generic versions of the drug can be offered for sale if the FDA agrees; "generic drugs are usually cheaper than brand-name drugs"
References in periodicals archive ?
The researchers identified the most-prescribed brand-name drug in each category: the statin rosuvastatin, the beta-blocker nebivolol, the ARB olmesartan, and the SNRI desvenlafaxine.
In Fulgenzi, the brand-name drug Reglan received approval from the Food and Drug Administration to add the phrase "Therapy should not exceed 12 weeks in duration" to its label.
The battle between generic and brand-name drug companies has escalated.
For the first time, we know that brand-name drug retail prices are growing just as quickly as manufacturer prices," says AARP executive vice president John Rother.
The 2010 deals protect $9 billion in brand-name drug sales from generic competition, FTC Chairman Jon Leibowitz told a House subcommittee.
The active ingredients in brand-name and generic drugs are exactly the same, and the FDA requires the generic to meet all the standards of the brand-name drug in terms of strength, purity, and more.
This happens as a result of brand-name drug makers settling lawsuits by generic drug makers to avoid any patent-infringement lawsuits in the future.
From 2000 to 2008, 416 brand-name drug products--different drug strengths and dosage forms of the same drug brands--had extraordinary price increases.
Policies for brand-name drug coverage, if available, would be much more expensive than the generic alternatives.
My concern is that I won't be getting the same effect from a generic drug that I would get from a brand-name drug.
Together, these three books offer consumers ample reason to ask questions before filling a prescription, and to think twice before going to the doctor to demand a brand-name drug.
Under data exclusivity, a controversial rule first imposed in 1987, for a period of about eight years after approval of a new drug, a country cannot accept an application for a generic bioequivalent to a brand-name drug even if the patent is expired or is otherwise not a problem, because that is called "unfair" use of the knowledge that the brand-name drug worked in the first place.